Tübingen, Germany, Might 11, 2022 Acousia Therapeutics GmbH will probably be presenting knowledge on the corporate’s medical stage, first-in-class lead candidate ACOU085 on the Hanson Wade 2nd Internal Ear Therapeutics Summit to be held in particular person in Boston (MA) from June 20–23, 2022.
ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is presently being examined in a Part 1b medical trial involving age-related listening to loss (ARHL) sufferers. Designed to modulate a biologically validated goal – the KCNQ4-encoded Kv7.4 potassium channel, which is important for sustaining auditory operate – ACOU085 is being developed for the remedy and prevention of listening to loss for numerous acquired and inherited types of sensorineural listening to loss.
ACOU085 is characterised by a singular twin mode of motion, which offers acute purposeful enhancement and long-term safety for the terminally differentiated sensorineural outer hair cells. “Being invited to share the translational background and progress of our ACOU085 lead program with the listening to loss drug growth group on the Internal Ear Therapeutics Summit is an thrilling alternative for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Chief Growth Officer at Acousia Therapeutics. “I sit up for stimulating discussions with our friends in Boston.”
Along with receiving an invite to current “Small Molecule, KCNQ4 Agonist ACOU085 for the Remedy and Prevention of Listening to Loss”, Dr. Dyhrfjeld-Johnsen can even take part as a panelist on the panel dialogue “De-risking the Early Growth Course of: A Sturdy and Complete Early Growth Course of Is Important to Reduce Setbacks Confronted within the Clinic” and within the workshop “Thoughts The Hole: Calling Out the Shortfalls within the Present Internal Ear Therapeutic Growth Pathway and Illuminating Options”.
About Acousia Therapeutics
Acousia Therapeutics GmbH is a privately-held, medical stage biotech firm primarily based in Tübingen, Germany. The corporate is devoted to the identification and growth of small molecules for efficient prevention and remedy of various etiologies of listening to loss. Acousia Therapeutics develops medicine for native and systemic administration.